144P Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial. (December 2022) - Yan, S.; Wang, J.; Lyu, C.; Bi, J.; Xin, Y.; Liu, B.; Li, S.; Wang, Y.; Chen, J.; Li, X.; Yang, Y.; Wu, N.